On August 25, I published my initial analysis of the world market leader in animal health, Zoetis Inc. ( ZTS ). My rating at the time: Buy. Since then, however, the stock has continued to lose value. Following theWith 14 years of experience as a financial advisor at a Italian bank, I’ve helped over 1,000 clients manage their finances successfully. In 2018, I turned my passion into a profession and have since been writing fundamental equity research for various German-language investor platforms. From 2019 t ...

Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live chat discussion of the sector.Sign up today for your two-week free trial and get a new lease on oil & gas! ...

Getty Images Holdings, Inc. (NYSE:GETY) is set to release its quarterly earnings with an expected EPS of $0.04 and revenue of $240 million.Getty Images is involved in a legal battle against Stability AI, highlighting issues around copyright and AI in the media industry.Getty Images Holdings, Inc. (NYSE:GETY) is a prominent player in the global visual content industry, providing a vast array of images and videos to businesses and consumers. As a key marketplace for visual content, Getty Images faces competit ...

The consensus price target for Coya Therapeutics, Inc. (NASDAQ:COYA) has remained stable at $17, with a slightly higher target of $18 from analyst Raghuram Selvaraju.Recent 10.7% increase in share price reflects investor optimism, despite the lack of sustained improvement in earnings estimate revisions.Future clinical trial results or regulatory approvals are key to the company's stock performance and future price targets.Coya Therapeutics, Inc. (NASDAQ:COYA) is a clinical-stage biotechnology company dedica ...

Shares of Take-Two Interactive were among the S&P 500's big decliners today. Chris Delmas / AFP via Getty Images Close Key Takeaways Some of the biggest video-game news of the season is about a game that isn't even expected this year—though it was once. Shares of Take-Two Interactive (TTWO) on Friday fell 8%, putting it among the S&P 500's bigger decliners, following last night's news that the company will postpone the release of one of the industry's highest-profile games—the sixth installment in the "Gran ...

As an avid Booking Holdings ( BKNG ) user, I was curious as to the company's business model and valuation, and about a year ago, I analyzed this great stock and its peerExperience is difficult to learn. After 30 plus years of critically analyzing the nuts and bolts of businesses as diverse as airlines, oil, retail, mining to fintech and ecommerce plus the macro, monetary and political drivers. I continue to immensely enjoy learning and applying my experience to unravel, comprehend and benefit from new ideas ...

Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, Alpha-X & Alpha DRK and Montréal ExchangeToronto, Ontario--(Newsfile Corp. - November 7, 2025) - TMX Group Limited today announced October 2025 trading statistics for its marketplaces - Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange (Alpha), including Alpha-X & Alpha DRK, and Montréal Exchange (MX).All TMX Equities Marketplaces *October 2025September 2025October 2024Volume 18,846,129,48217,189,380,70711,818,894,460Value $38 ...

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster on its novel OSE-Cytomask® Cis-Demasking1 immunocytokine technology at the Society for Immunotherapy of Cancer (SITC) 2025 Annual M ...

The company's financial performance was negatively impacted by higher operational costs and a decline in gold output. This has led to a cautious outlook from analysts, as highlighted by Heiko Ihle's $7 price target. The recent earnings report, which did not meet market expectations, resulted in a 4.78% drop in the company's shares, erasing gains made earlier in the week. Endeavour Silver's recent earnings call featured key company participants, including CEO Daniel W. Dickson. The call provided insights int ...

Calumet, Inc. (NASDAQ:CLMT) is a diversified manufacturer and marketer specializing in specialty branded products for consumer and industrial markets. The company operates through its segments: Specialty Products and Solutions, Montana/Renewables, and Performance Brands, offering a wide range of products such as solvents, lubricating oils, renewable fuels, and high-performance consumer products.The stock consensus target price for Calumet has experienced fluctuations over the past year. Last month, the aver ...